ESPR Esperion Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

ESPR [NASD]

Esperion Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-3.30	Insider Own	0.40%	Shs Outstand	27.67M	Perf Week	-8.00%
Market Cap	886.26M	Forward P/E	-	EPS next Y	-9.95	Insider Trans	0.00%	Shs Float	27.55M	Perf Month	-10.37%
Income	-84.00M	PEG	-	EPS next Q	-3.44	Inst Own	-	Short Float	40.43%	Perf Quarter	-20.93%
Sales	216.00M	P/S	4.10	EPS this Y	52.50%	Inst Trans	0.36%	Short Ratio	18.82	Perf Half Y	-20.32%
Book/sh	3.09	P/B	10.46	EPS next Y	-105.30%	ROA	-34.30%	Target Price	-	Perf Year	-18.84%
Cash/sh	10.96	P/C	2.95	EPS next 5Y	28.30%	ROE	-271.50%	52W Range	24.82 - 76.98	Perf YTD	-45.82%
Dividend	-	P/FCF	-	EPS past 5Y	-10.10%	ROI	-467.80%	52W High	-58.03%	Beta	1.66
Dividend %	-	Quick Ratio	3.70	Sales past 5Y	-	Gross Margin	99.80%	52W Low	30.18%	ATR	1.68
Employees	193	Current Ratio	3.80	Sales Q/Q	21512.60%	Oper. Margin	-32.40%	RSI (14)	42.41	Volatility	4.46% 4.64%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	314.80%	Profit Margin	-38.90%	Rel Volume	0.58	Prev Close	31.85
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 02 AMC	Payout	-	Avg Volume	591.99K	Price	32.31
Recom	1.80	SMA20	-6.60%	SMA50	-8.14%	SMA200	-25.57%	Volume	345,913	Change	1.44%

Sep-29-20

Resumed

JP Morgan

Underweight

$35

Aug-11-20

Downgrade

Credit Suisse

Outperform → Neutral

$83 → $45

Apr-01-20

Resumed

BofA/Merrill

Buy

$50

Mar-17-20

Upgrade

Citigroup

Neutral → Buy

Feb-24-20

Downgrade

Northland Capital

Outperform → Market Perform

$60

Feb-14-20

Downgrade

Citigroup

Buy → Neutral

$82

Sep-16-19

Upgrade

Goldman

Sell → Neutral

$55 → $45

May-29-19

Downgrade

Goldman

Neutral → Sell

May-06-19

Upgrade

BofA/Merrill

Underperform → Neutral

Apr-26-19

Upgrade

Goldman

Sell → Neutral

$50

Mar-13-19

Upgrade

JP Morgan

Underweight → Neutral

$38 → $47

Jan-07-19

Reiterated

Needham

Strong Buy

$94 → $114

Dec-13-18

Initiated

Goldman

Sell

$45

Oct-29-18

Upgrade

Northland Capital

Market Perform → Outperform

Oct-16-18

Initiated

BTIG Research

Buy

$82

Aug-17-18

Upgrade

Citigroup

Neutral → Buy

Jul-11-18

Downgrade

Northland Capital

Outperform → Market Perform

May-03-18

Downgrade

JP Morgan

Neutral → Underweight

$41

May-02-18

Downgrade

BofA/Merrill

Buy → Underperform

Mar-27-18

Reiterated

Chardan Capital Markets

Neutral

$75 → $100

Oct-19-20 08:00AM	Esperion to Report Third Quarter 2020 Financial Results November 2, 2020 GlobeNewswire
Oct-13-20 03:04PM	Do Hedge Funds Love Esperion Therapeutics (ESPR)? Insider Monkey
Oct-07-20 08:00AM	NEXLETOL® (bempedoic acid) Tablets Highlighted in EAS 2020 Presentation of Analysis Demonstrating Significant Cholesterol Lowering in People with Familial Hypercholesterolemia GlobeNewswire
Sep-28-20 04:06PM	Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol GlobeNewswire
Sep-22-20 08:56AM	Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) Intrinsic Value Is Potentially 33% Above Its Share Price Simply Wall St.
Sep-02-20 08:41AM	Esperion to Participate in Two Upcoming Virtual Investor Conferences GlobeNewswire
Aug-26-20 09:07AM	Esperion Announces Two Data Presentations of NEXLETOL® (bempedoic acid) Tablet at the ESC Congress 2020 GlobeNewswire
Aug-21-20 04:05PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -5.10%
Aug-11-20 11:10AM	Esperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by Coronavirus Zacks -9.51%
02:30AM	Esperion Therapeutics Inc (ESPR) Q2 2020 Earnings Call Transcript Motley Fool
Aug-10-20 05:15PM	Esperion Therapeutics (ESPR) Beats Q2 Earnings Estimates Zacks
04:04PM	Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update GlobeNewswire
Aug-07-20 09:27AM	Were Hedge Funds Right About Betting On Esperion Therapeutics (ESPR)? Insider Monkey
Aug-06-20 10:05AM	Esperion Therapeutics'(NASDAQ:ESPR) Share Price Is Down 42% Over The Past Five Years. Simply Wall St.
Aug-03-20 07:26AM	Esperion to Report Second Quarter 2020 Financial Results August 10, 2020 GlobeNewswire +7.41%
Jul-16-20 07:16PM	Esperion Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold Investor's Business Daily
Jul-01-20 11:12AM	Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bempedoic acid) Tablets GlobeNewswire
Jun-23-20 11:42AM	Esperion Therapeutics, Inc. (ESPR): Hedge Funds Are Getting Bullish Insider Monkey
Jun-22-20 07:00AM	Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement GlobeNewswire +7.93%
Jun-16-20 03:09PM	Robinhood traders could learn from this growth-stock investor whos beaten indexes by a wide margin for years MarketWatch
Jun-14-20 09:30AM	Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions GlobeNewswire
Jun-12-20 10:20AM	Edited Transcript of ESPR earnings conference call or presentation 6-May-20 8:30pm GMT Thomson Reuters StreetEvents
07:19AM	Esperion Confirms NEXLETOL (bempedoic acid) Tablets to be Included in Assessment of Non-statin Medicines for Hypercholesterolemia by ICER GlobeNewswire
Jun-08-20 08:00AM	Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference GlobeNewswire +5.38%
Jun-05-20 11:31AM	Why Is Esperion Therapeutics (ESPR) Down 1.5% Since Last Earnings Report? Zacks
Jun-04-20 12:00PM	All You Need to Know About Esperion Therapeutics (ESPR) Rating Upgrade to Buy Zacks
07:00AM	Esperion Announces Commercial Availability of NEXLIZET (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering GlobeNewswire
May-27-20 08:00AM	Esperion to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference 2020 GlobeNewswire
May-15-20 06:00PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
May-08-20 02:49PM	Analysts Are Upgrading Esperion Therapeutics, Inc. (NASDAQ:ESPR) After Its Latest Results Simply Wall St. +5.55%
May-07-20 11:47AM	Esperion (ESPR) Q1 Earnings and Revenues Beat Estimates Zacks +8.67%
09:01AM	Esperion Therapeutics Inc (ESPR) Q1 2020 Earnings Call Transcript Motley Fool
08:00AM	Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference GlobeNewswire
May-06-20 06:55PM	Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	Esperion Reports First Quarter 2020 Financial Results and Provides Company Update GlobeNewswire
Apr-30-20 08:00AM	Esperion to Report First Quarter 2020 Financial Results May 6, 2020 GlobeNewswire
Apr-21-20 07:01AM	Industry Analysts Just Upgraded Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Forecasts By 15% Simply Wall St.
Apr-20-20 07:00AM	Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Tablets in Japan GlobeNewswire +7.14%
Apr-18-20 10:59AM	Were Hedge Funds Right About Selling Esperion Therapeutics (ESPR)? Insider Monkey
Apr-09-20 08:00AM	Esperion to Participate in Fireside Chat at the 19th Annual Needham Virtual Healthcare Conference GlobeNewswire
Apr-07-20 10:43AM	Esperion's Cholesterol Drugs Receive Approval in Europe Zacks
Apr-06-20 07:05AM	Esperion Announces European Commission Approval of the NUSTENDI (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia GlobeNewswire
07:00AM	Esperion Announces European Commission Approval of the NILEMDO (bempedoic acid) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia GlobeNewswire
Apr-05-20 08:26AM	Revenue Downgrade: Here's What Analysts Forecast For Esperion Therapeutics, Inc. (NASDAQ:ESPR) Simply Wall St.
Mar-30-20 04:15PM	Esperion Announces Commercial Availability of the NEXLETOL (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare GlobeNewswire
Mar-28-20 11:30AM	Esperion Therapeutics (ESPR) Down 32.5% Since Last Earnings Report: Can It Rebound? Zacks
09:30AM	Esperion Announces Three Data Presentations of the NEXLETOL (bempedoic acid) Tablet and the NEXLIZET (bempedoic acid and ezetimibe) Tablet at the American College of Cardiologys 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) GlobeNewswire
Mar-23-20 07:30AM	Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiologys 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) GlobeNewswire
Mar-18-20 07:30AM	Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors GlobeNewswire +8.53%
Feb-28-20 04:15PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:12AM	Esperion (ESPR) Q4 Earnings and Revenues Beat Estimates Zacks
07:00AM	Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
Feb-27-20 10:15AM	Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates Zacks -8.33%
07:35AM	The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy Benzinga
07:00AM	Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-26-20 05:30PM	Esperion Announces FDA Approval of the NEXLIZET (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine GlobeNewswire
Feb-21-20 04:38PM	Esperion Announces FDA Approval of NEXLETOL (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine GlobeNewswire -9.64%
04:27PM	Biotech Stock Crumbles Despite Esperion Nabbing A Key Drug Approval Investor's Business Daily
Feb-16-20 03:03PM	The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions Benzinga
Feb-03-20 01:30PM	Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates Benzinga +5.68%
Jan-31-20 07:02AM	Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia GlobeNewswire
07:01AM	Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia GlobeNewswire
Jan-27-20 12:20PM	One Thing To Remember About The Esperion Therapeutics, Inc. (NASDAQ:ESPR) Share Price Simply Wall St.
Jan-07-20 07:30AM	Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-20 04:15PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Dec-12-19 11:59AM	Did Hedge Funds Drop The Ball On Esperion Therapeutics (ESPR) ? Insider Monkey
Dec-06-19 11:31AM	Esperion Therapeutics (ESPR) Up 25.1% Since Last Earnings Report: Can It Continue? Zacks +6.30%
Nov-28-19 07:09AM	Esperion's Promising Drugs Under Review, Funds a Concern Zacks
Nov-22-19 06:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +5.25%
Nov-19-19 09:13AM	Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10% Zacks
Nov-17-19 03:05PM	Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions GlobeNewswire
Nov-12-19 11:05AM	Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results GlobeNewswire
Nov-10-19 07:56AM	President Timothy Mayleben Just Bought Shares In Esperion Therapeutics, Inc. (NASDAQ:ESPR) Simply Wall St.
Nov-09-19 09:26AM	Is Esperion Therapeutics's (NASDAQ:ESPR) Share Price Gain Of 215% Well Earned? Simply Wall St.
Nov-07-19 11:04AM	Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3 Zacks
07:30AM	Esperion to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-06-19 08:45AM	Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates Zacks -8.65%
07:30AM	Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results GlobeNewswire
Nov-04-19 07:30AM	Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions GlobeNewswire
Oct-29-19 07:30AM	Esperion to Report Third Quarter 2019 Financial Results November 6, 2019 GlobeNewswire
Oct-28-19 05:15PM	Should You Buy Esperion Therapeutics, Inc. (ESPR)? Insider Monkey
Oct-25-19 10:00AM	Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List GlobeNewswire
Oct-04-19 08:34AM	Here's Why We're Not At All Concerned With Esperion Therapeutics's (NASDAQ:ESPR) Cash Burn Situation Simply Wall St.
Sep-09-19 10:57AM	7 Micro-Cap and Small-Cap Stocks That Insiders Are Buying InvestorPlace
Sep-07-19 09:30AM	Esperion Therapeutics (ESPR) Down 10.8% Since Last Earnings Report: Can It Rebound? Zacks
Sep-06-19 06:15PM	Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $259,125 of Shares GuruFocus.com
Aug-30-19 04:15PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
10:26AM	Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study Zacks
Aug-29-19 07:30AM	Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes GlobeNewswire
Aug-26-19 11:05AM	Esperion's Drugs in Review Hold Potential, Funds a Concern Zacks
Aug-20-19 11:15AM	Does Market Volatility Impact Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) Share Price? Simply Wall St.
Aug-09-19 08:06AM	Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat Zacks
Aug-08-19 09:15AM	Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:30AM	Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results GlobeNewswire
Aug-06-19 04:15PM	Esperion to Present at the BTIG Biotechnology Conference GlobeNewswire
Aug-02-19 07:15PM	Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $197,800 of Shares GuruFocus.com
Jul-31-19 01:48PM	Steven Cohen Charges Into Chiasma GuruFocus.com
Jul-30-19 04:15PM	Esperion to Report Second Quarter 2019 Financial Results August 8, 2019 GlobeNewswire
03:16PM	A Firm's First Profit Can Mean Big Returns for Investors Zacks
Jul-29-19 08:08AM	3 Biotech Stocks Corporate Insiders are Buying TipRanks

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MAYLEBEN TIMOTHY M	President & CEO	Mar 11	Buy	43.00	2,500	107,500	111,998	Mar 12 07:34 AM
MAYLEBEN TIMOTHY M	President & CEO	Feb 28	Buy	49.00	5,000	245,000	109,498	Mar 02 06:16 AM
BIOTECH TARGET N V	10% Owner	Jan 23	Buy	52.12	20,000	1,042,398	3,747,964	Jan 27 12:51 PM
MAYLEBEN TIMOTHY M	President & CEO	Nov 06	Buy	36.98	5,000	184,900	83,663	Nov 08 04:14 PM
BIOTECH TARGET N V	10% Owner	Nov 06	Buy	37.30	75,000	2,797,560	3,727,964	Nov 08 02:54 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience